期刊
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
卷 113, 期 29, 页码 8098-8103出版社
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1600816113
关键词
nanotechnology; Toll-like receptor; dendritic cells; lymph node; vaccine
资金
- Research Foundation-Flanders (FWO)
- Flemish Liga Against Cancer
- FWO postdoctoral grant
- Alexander von Humboldt Foundation postdoctoral Feodor Lynen research fellowship
- Special Research Fund (BOF)-UGent
- National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) [HSN272200900033C]
- Agency for Innovation by Science and Technology (IWT) Flanders PhD scholarships
Agonists of Toll-like receptors (TLRs) are potent activators of the innate immune system and hold promise as vaccine adjuvant and for anticancer immunotherapy. Unfortunately, in soluble form they readily enter systemic circulation and cause systemic inflammatory toxicity. Here we demonstrate that by covalent ligation of a small-molecule imidazoquinoline-based TLR7/8 agonist to 50-nm-sized degradable polymeric nanogels the potency of the agonist to activate TLR7/8 in in vitro cultured dendritic cells is largely retained. Importantly, imidazoquinoline-ligated nanogels focused the in vivo immune activation on the draining lymph nodes while dramatically reducing systemic inflammation. Mechanistic studies revealed a prevalent passive diffusion of the nanogels to the draining lymph node. Moreover, immunization studies in mice have shown that relative to soluble TLR7/8 agonist, imidazoquinoline-ligated nanogels induce superior antibody and T-cell responses against a tuberculosis antigen. This approach opens possibilities to enhance the therapeutic benefit of small-molecule TLR agonist for a variety of applications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据